公开(公告)号：US10548877B2

公开(公告)日：2020-02-04

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Kouji Fuji ,  Tomohiro Ohashi ,  Makoto Fushimi ,  Kei Masuda ,  Tatsuki Koike ,  Takeshi Wakabayashi ,  Jinichi Yonemori ,  Masami Yamada

IPC: A61K31/4192 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/4439 ,  A61P25/20 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  C07D213/56 ,  C07D231/12 ,  C07D249/06 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.